Journal: Clinical Science (London, England : 1979)
Article Title: Neuregulin modulates hormone receptor levels in breast cancer through concerted action on multiple signaling pathways
doi: 10.1042/CS20220472
Figure Lengend Snippet: Soluble NRG binds and activates ErbB/HER receptors and triggers the activation of several intracellular signaling pathways (ERK1/2, ERK5, and PI3K-AKT-mTOR). These pathways regulate simultaneously ERα phosphorylation at serines 118 and 167 and their expression levels through the proteasome or at the transcriptional level. Furthermore, simultaneously activation of these signaling pathways by NRG receptors induce resistance to fulvestrant. Inhibitors used to block the different signaling pathways are shown in red.
Article Snippet: The ERK5 inhibitor JWG071 was from Glixx Laboratories Inc (Hopkinton, MA, U.S.A.).
Techniques: Activation Assay, Protein-Protein interactions, Phospho-proteomics, Expressing, Blocking Assay